Warning: The NCBI web site requires JavaScript to function. more...
Generate a file for use with external citation management software.
Departamento de Anestesiología, Hospital Clínico Pontificia Universidad Católica de Chile, Santiago, Chile. ralopez@puc.cl
Recombinant activated factor VII (rFVIIa) is a new haemostatic drug, originally used for the treatment of patients with hemophilia A and B. At the present time it is used for other bleeding conditions such as the perioperative period. When used prophylactically there is a reduction in the number of bleeding episodes but no changes in the need for blood transfusion or other blood products. The adverse effects are arterial or venous thromboembolic events that are mostly related to the severity of the underlying disease of the patient and the concurrent administration of other haemostatic agents, rather than the use of rFVIIa. Its use is recommended when there is a persistent bleeding after the reposition of blood products and when surgical causes of bleeding have been discarded. The cost of the medication should also be considered before its use.
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on